Statement of Changes in Beneficial Ownership (4)
2022年9月14日 - 5:16AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Costantino Robert J |
2. Issuer Name and Ticker or Trading Symbol
Cure Pharmaceutical Holding Corp.
[
CURR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O CURE PHARMACEUTICAL HOLDING CORP., 5805 SEPULVEDA BLVD., SUITE 801 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/12/2022 |
(Street)
SHERMAN OAKS, CA 91411
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 8/12/2022 (1) | | A | | 226764 (2) | A | $0 | 953621 | D | |
Common Stock | | | | | | | | 22400 | I | See footnote (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | This late filing is due to an inadvertent administrative error and not any error of the Reporting Person. |
(2) | Represents the grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan pursuant to the Issuer's Non-Employee Director Compensation Policy. The RSUs will vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service through the vesting date. The RSUs will vest in full immediately prior to the consummation of a change in control of the Issuer. The RSUs will be settled in shares of the Issuer's common stock upon vesting. |
(3) | Held in a Rollover IRA by the spouse of the Reporting Person, as reported on Form 3 filed with the Securities and Exchange Commission on August 19, 2022. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Costantino Robert J C/O CURE PHARMACEUTICAL HOLDING CORP. 5805 SEPULVEDA BLVD., SUITE 801 SHERMAN OAKS, CA 91411 | X |
|
|
|
Signatures
|
/s/ Joel M. Bennett, Attorney-in-Fact for Robert J. Costantino | | 9/13/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Cure Pharmaceutical (PK) (USOTC:CURR)
過去 株価チャート
から 5 2024 まで 6 2024
Cure Pharmaceutical (PK) (USOTC:CURR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Cure Pharmaceutical Holding Corporation (PK) (その他OTC): 0 recent articles
その他のCure Pharmaceutical Holding Corp.ニュース記事